Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity.
Ketola K, Kaljunen H, Taavitsainen S, Kaarijärvi R, Järvelä E, Rodríguez-Martín B, Haase K, Woodcock DJ, Tubio J, Wedge DC, Nykter M, Bova GS. Ketola K, et al. Among authors: nykter m. Cancer Res. 2021 Oct 1;81(19):4901-4909. doi: 10.1158/0008-5472.CAN-21-0371. Epub 2021 Sep 8. Cancer Res. 2021. PMID: 34348967 Free PMC article.
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS, Visakorpi T. Leinonen KA, et al. Among authors: nykter m. Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T. Epub 2013 Oct 1. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 24083995 Free PMC article.
The evolutionary history of lethal metastatic prostate cancer.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC; ICGC Prostate Group; Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS. Gundem G, et al. Among authors: nykter m. Nature. 2015 Apr 16;520(7547):353-357. doi: 10.1038/nature14347. Epub 2015 Apr 1. Nature. 2015. PMID: 25830880 Free PMC article.
Epigenetically altered miR-193b targets cyclin D1 in prostate cancer.
Kaukoniemi KM, Rauhala HE, Scaravilli M, Latonen L, Annala M, Vessella RL, Nykter M, Tammela TL, Visakorpi T. Kaukoniemi KM, et al. Among authors: nykter m. Cancer Med. 2015 Sep;4(9):1417-25. doi: 10.1002/cam4.486. Epub 2015 Jul 1. Cancer Med. 2015. PMID: 26129688 Free PMC article.
Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
Sjöblom L, Saramäki O, Annala M, Leinonen K, Nättinen J, Tolonen T, Wahlfors T, Nykter M, Bova GS, Schleutker J, Tammela TL, Lilja H, Visakorpi T. Sjöblom L, et al. Among authors: nykter m. PLoS One. 2016 Mar 3;11(3):e0150241. doi: 10.1371/journal.pone.0150241. eCollection 2016. PLoS One. 2016. PMID: 26939004 Free PMC article.
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN. Annala M, et al. Among authors: nykter m. Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24. Cancer Discov. 2018. PMID: 29367197 Clinical Trial.
174 results